Tell us about your search experience on the TGA website - complete our short survey
TGA grants provisional determination to Celltrion Healthcare Australia Pty Ltd's antiviral COVID-19 treatment regdanvimab
On 20 August 2021 the TGA granted provisional determination to Celltrion Healthcare Australia Pty Ltd in relation to regdanvimab.
Published
Related content
- TGA grants provisional determination to Roche Products Pty Ltd combination COVID-19 treatment casirivimab + imdevimab (RONAPREVE)On 20 August 2021 the TGA granted provisional determination to Roche Products Pty Ltd in relation to the combination therapy casirivimab + imdevimab (RONAPREVE)
- TGA Provisional Approval of Celltrion Healthcare Australia Pty Ltd COVID-19 treatment, regdanvimab (REGKIRONA)TGA grants provisional approval to Celltrion Healthcare Australia Pty Ltd for COVID-19 treatment, regdanvimab (REGKIRONA)
- TGA grants provisional determination to Merck Sharp & Dohme's antiviral COVID-19 treatment MolnupiravirOn 9 August 2021 the TGA granted provisional determination to Merck Sharp & Dohme (Australia) Pty Ltd (MSD) in relation to Molnupiravir.